Cargando…

Association of prior statin therapy with cytokine profiles and outcomes in patients hospitalized with community acquired pneumonia

Detalles Bibliográficos
Autores principales:	Milbrandt, E, Kellum, J, Kong, L, Weissfeld, L, Martinez, J, Angus, D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2005
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4098303/ http://dx.doi.org/10.1186/cc3216

Ejemplares similares

Coagulation in hospitalized community-acquired pneumonia: disturbances in even the least ill
por: Reade, MC, et al.
Publicado: (2008)

Racial disparities in quality of care in community-acquired pneumonia
por: Mayr, FB, et al.
Publicado: (2008)

Mathematical modeling of community-acquired pneumonia patients
por: Sarkar, J, et al.
Publicado: (2009)

The prevalence of anemia and its association with 90-day mortality in hospitalized community-acquired pneumonia
por: Reade, Michael C, et al.
Publicado: (2010)

Age-related differences of outcomes in patients hospitalized with community-acquired pneumonia are not explained by differences in immune response
por: Kale, S, et al.
Publicado: (2010)

Use of statins in community-acquired pneumonia in intensive care settings: is there a survival advantage?
por: Khanna, A, et al.
Publicado: (2011)

ICU use of haloperidol prior to the 2002 SCCM sedation and analgesia guidelines
por: Milbrandt, E, et al.
Publicado: (2004)

Community-acquired pneumonia treated on the ICU
por: Apostolidou, E, et al.
Publicado: (2006)

The timing of new acute hemodynamic events in ICU patients
por: Kersten, A, et al.
Publicado: (2004)

Outcome of severe community-acquired pneumonia: the impact of comorbidities
por: Pereira, JM, et al.
Publicado: (2013)

Severe community-acquired pneumonia in the intensive care unit
por: Costa, C, et al.
Publicado: (2005)

Systemic corticosteroids for community-acquired pneumonia in adults
por: Pugh, RJ, et al.
Publicado: (2012)

Middle molecules in severe community-acquired pneumonia
por: Dumitras, T, et al.
Publicado: (2015)

Severity of illness scoring systems in community-acquired Legionella pneumonia
por: Simonsen, Ø, et al.
Publicado: (2010)

Prognostic assessment in community-acquired pneumonia by pneumonia severity scores and biomarkers
por: Dusemund, F, et al.
Publicado: (2010)

Hospital-acquired pneumonia is associated with deficient γc-cytokine gene expression
por: White, M, et al.
Publicado: (2011)

Severe community-acquired pneumonia: risk factors for in-hospital mortality
por: Pereira, JM, et al.
Publicado: (2012)

Host genetic variants associated with community-acquired pneumonia
por: Salnikova, LE, et al.
Publicado: (2013)

Association of C-Reactive Protein and Outcome in Patients With Community-Acquired Pneumonia
por: Park, JK, et al.
Publicado: (2015)

Prothrombotic state at hospital discharge increases 1-year mortality in pneumonia and sepsis survivors
por: Mayr, FB, et al.
Publicado: (2009)

Validation of predictive rules for ICU patients with community-acquired pneumonia
por: Rudnov, V, et al.
Publicado: (2008)

Simple and fast prediction of Legionella sp. in community-acquired pneumonia: validation of a prediction rule
por: Haubitz, S, et al.
Publicado: (2013)

Prognostic value of proadrenomedullin in severe sepsis and septic shock patients with community-acquired pneumonia
por: Suberviola, B, et al.
Publicado: (2011)

Beneficial effects of antiplatelet drugs in patients with community-acquired pneumonia and in endotoxin shock in mice
por: Winning, J, et al.
Publicado: (2007)

A new severity score for community-acquired pneumonia: PARB score
por: Uchiyama, N, et al.
Publicado: (2010)

Criteria of the systemic inflammatory response syndrome in patients with community-acquired pneumonia
por: Ustyantseva, I, et al.
Publicado: (2006)

The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia
por: Mortensen, Eric M, et al.
Publicado: (2005)

Pre-analytic factors and initial biomarker levels in community- acquired pneumonia patients
por: Kutz, A, et al.
Publicado: (2014)

Analysis of the mortality rate in patients admitted to the ICU for severe community-acquired pneumonia
por: Joya-Montosa, C, et al.
Publicado: (2015)

Procalcitonin guidance significantly reduces antibiotic duration in community-acquired pneumonia: the 'ProCAP' study
por: Christ-Crain, M, et al.
Publicado: (2005)

Severe pneumonia in critically ill cancer patients: clinical outcomes and a comparison between healthcare-associated pneumonia and community-acquired pneumonia
por: Rabello, Ligia SCF, et al.
Publicado: (2013)

Sunlight exposure does not influence ICU survival
por: Castro, R, et al.
Publicado: (2011)

Effects of systemic steroid in patients with severe community-acquired pneumonia requiring mechanical ventilation
por: Chon, G, et al.
Publicado: (2009)

Defining severe community-acquired pneumonia: a significant barrier to improving patient outcomes
por: Balp, MM, et al.
Publicado: (2009)

Assessment of specific risk scores for patients admitted to the ICU for severe community-acquired pneumonia
por: Joya-Montosa, C, et al.
Publicado: (2015)

Does the use of a cytokine 'filter' during cardiopulmonary bypass make sense?
por: Clermont, G, et al.
Publicado: (2004)

Comparison of CURB-65 and CRB-65 as predictors of death in community-acquired pneumonia in adults admitted to an ICU
por: Santana, AR, et al.
Publicado: (2013)

Adverse events and death in patients with community-acquired pneumonia in the emergency department of a major university hospital in Brazil
por: Machado, A, et al.
Publicado: (2005)

Adjunct prednisone therapy for patients with community-acquired pneumonia: a randomized, placebo-controlled multicenter trial
por: Blum, CA, et al.
Publicado: (2015)

Community-acquired pneumonia: a comparison of clinical treatment failure in patients treated with either penicillin or cefuroxime
por: Ekloef, Josefin, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_amkipc8fni40b57c2n6en5t7no